Treatment

Lower-Cost Generic Tofacitinib Now Available in the U.S. 

A generic version of Xeljanz® (tofacitinib) is now available in the United States, with prices reported as low as $25–$150…

Q32 Bio Logo

Q32 Bio Reports Positive Phase 2 Results for Investigational Treatment for Severe to Very Severe Alopecia Areata in Adults

Q32 Bio has announced positive 36-week topline results from Part B of its Phase 2 SIGNAL-AA clinical trial evaluating bempikibart,…

Nektar Therapeutics Announces Positive Results from Phase 2B Study for the Treatment of Alopecia Areata

Nektar Therapeutics announced today new results from its Phase 2b REZOLVE-AA study testing rezpegaldesleukin (REZPEG)—an experimental immune-modulating drug—in adults with…

LEQSELVI (Deuruxolitinib) Now Available in U.S. for Adults with Severe Alopecia Areata

Sun Pharmaceutical Industries Limited (Sun Pharma) today announced LEQSELVI™ (deuruxolitinib) is now commercially available for the treatment of severe alopecia…

FDA Approves LEQSELVI™ for Adults with Severe Alopecia Areata

Today, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, marking the third FDA-approved treatment for…

FDA Approves LITFULO™ (Ritlecitinib) for Adults and Children ages 12+ with Severe Alopecia Areata

Today, the U.S. Food and Drug Administration (FDA) approved LITFULO™ for severe alopecia areata, marking the second FDA-approved treatment for…

Treatment for Alopecia Areata Receives FDA Approval

Treatment for Alopecia Areata Receives FDA Approval On June 13, 2022, the U.S. Food and Drug administration (FDA) approved Olumiant…

FDA Approves Olumiant™ (baricitinib) for Adults with Severe Alopecia Areata

Today, history was made as the U.S. Food and Drug Administration (FDA) approved Olumiant™ for alopecia areata, marking the first…